Overview

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.
Details
Lead Sponsor:
Bayer
Treatments:
Sorafenib